Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alumis Inc. stock logo
ALMS
Alumis
$4.78
-2.4%
$3.80
$2.76
$13.11
$509.92M-1.47721,521 shs605,132 shs
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$9.31
$10.03
$8.50
$23.00
$58.21MN/A37,647 shs794 shs
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
$5.53
+0.2%
$4.65
$1.94
$6.28
$294.21M0.41.19 million shs6.82 million shs
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
$4.57
+2.0%
$4.79
$4.00
$10.37
$239.75M0.32262,009 shs83,921 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alumis Inc. stock logo
ALMS
Alumis
+1.24%+1.03%+26.29%+10.11%-61.60%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00%-4.02%-6.71%-37.52%+930,999,900.00%
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
+13.81%+15.48%-1.43%+55.93%+2.79%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-5.68%+1.59%-13.51%-23.68%-10.22%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alumis Inc. stock logo
ALMS
Alumis
2.623 of 5 stars
3.60.00.00.01.81.71.3
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
4.2849 of 5 stars
3.25.00.04.21.91.70.6
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
2.443 of 5 stars
3.81.00.00.02.71.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alumis Inc. stock logo
ALMS
Alumis
3.13
Buy$20.17321.90% Upside
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00
N/AN/AN/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
2.33
Hold$12.00117.00% Upside
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
3.50
Strong Buy$10.00118.82% Upside

Current Analyst Ratings Breakdown

Latest IZTC, TKNO, ALMS, and SCPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/25/2025
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$6.00
8/25/2025
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
8/15/2025
Alumis Inc. stock logo
ALMS
Alumis
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$23.00 ➝ $22.00
8/14/2025
Alumis Inc. stock logo
ALMS
Alumis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
7/25/2025
Alumis Inc. stock logo
ALMS
Alumis
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$17.00
7/25/2025
Alumis Inc. stock logo
ALMS
Alumis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
7/22/2025
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$8.00
6/10/2025
Alumis Inc. stock logo
ALMS
Alumis
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$18.00
(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/A$4.66 per shareN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
$36.33M8.11N/AN/A($0.40) per share-13.83
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
$37.74M6.48N/AN/A$1.42 per share3.22
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alumis Inc. stock logo
ALMS
Alumis
-$294.23MN/A0.00N/AN/AN/A-119.15%-92.50%11/12/2025 (Estimated)
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/A0.00N/AN/AN/AN/AN/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
-$85.15M-$1.81N/AN/AN/A-183.55%-1,647.86%-71.76%11/12/2025 (Estimated)
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-$26.75M-$0.42N/AN/AN/A-55.24%-26.51%-18.40%11/6/2025 (Estimated)

Latest IZTC, TKNO, ALMS, and SCPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Alumis Inc. stock logo
ALMS
Alumis
-$1.11-$1.17-$0.06$0.77$1.80 million$2.67 million
8/7/2025Q2 2025
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
-$0.30-$0.34-$0.04-$0.34$15.41 million$16.04 million
8/7/2025Q2 2025
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-$0.1004-$0.07+$0.0304-$0.07$9.90 million$10.29 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
N/AN/AN/AN/AN/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alumis Inc. stock logo
ALMS
Alumis
N/A
6.05
6.05
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3.86
3.85
3.14
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
0.17
5.87
4.70

Institutional Ownership

CompanyInstitutional Ownership
Alumis Inc. stock logo
ALMS
Alumis
N/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
89.52%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
13.81%

Insider Ownership

CompanyInsider Ownership
Alumis Inc. stock logo
ALMS
Alumis
40.70%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
4.78%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
12.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alumis Inc. stock logo
ALMS
Alumis
N/A104.06 million61.71 millionN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
296.25 millionN/AN/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3053.30 million50.75 millionOptionable
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
24053.51 million46.83 millionNot Optionable

Recent News About These Companies

Alpha Teknova (NASDAQ:TKNO) Announces Earnings Results
Alpha Teknova (TKNO) Q2 Revenue Jumps 7%
Teknova Reports Second Quarter 2025 Financial Results
Alpha Teknova, Inc. (TKNO) Income Statement - Yahoo Finance
Teknova Reports First Quarter 2025 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alumis stock logo

Alumis NASDAQ:ALMS

$4.78 -0.12 (-2.45%)
Closing price 04:00 PM Eastern
Extended Trading
$4.78 +0.00 (+0.10%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Invizyne Technologies stock logo

Invizyne Technologies NASDAQ:IZTC

$9.31 0.00 (0.00%)
As of 08/22/2025

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

scPharmaceuticals stock logo

scPharmaceuticals NASDAQ:SCPH

$5.53 +0.01 (+0.18%)
Closing price 04:00 PM Eastern
Extended Trading
$5.50 -0.03 (-0.45%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Alpha Teknova stock logo

Alpha Teknova NASDAQ:TKNO

$4.57 +0.09 (+2.01%)
Closing price 04:00 PM Eastern
Extended Trading
$4.58 +0.01 (+0.33%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.